{"id":327,"date":"2026-07-29T21:16:35","date_gmt":"2026-07-29T20:16:35","guid":{"rendered":"https:\/\/peptidedeepdive.com\/?page_id=327"},"modified":"2026-09-23T12:37:31","modified_gmt":"2026-09-23T11:37:31","slug":"retatrutide","status":"publish","type":"page","link":"https:\/\/peptidedeepdive.com\/nl\/retatrutide\/","title":{"rendered":"Retatrutide"},"content":{"rendered":"\n<meta charset=\"utf-8\">\n<meta content=\"width=device-width, initial-scale=1.0\" name=\"viewport\">\n\n<link href=\"https:\/\/fonts.googleapis.com\" rel=\"preconnect\">\n<link crossorigin=\"\" href=\"https:\/\/fonts.gstatic.com\" rel=\"preconnect\">\n<link href=\"https:\/\/fonts.googleapis.com\/css2?family=IBM+Plex+Mono:wght@600&amp;display=swap\" rel=\"stylesheet\">\n<style>\n  :root{\n    --black:#0B0D0C;\n    --near-black:#111412;\n    --white:#FFFFFF;\n    --gray-bg:#F5F6F4;\n    --line:#E4E6E1;\n    --text-soft:#6B6F6C;\n    --emerald-bright:#92B9A4;\n    --emerald-pale:#E9F1ED;\n    --emerald-deep:#456C57;\n    --insert:#B65C42;\n    --insert-bg:#F5E4DD;\n    --max-w:760px;\n  }\n  *{box-sizing:border-box;}\n  html{scroll-behavior:smooth;}\n  body{\n    margin:0; background:var(--white); color:var(--black);\n    font-family:'Helvetica Neue', Helvetica, Arial, sans-serif; font-size:16px; line-height:1.65;\n    -webkit-font-smoothing:antialiased;\n  }\n  a{color:var(--emerald-deep);}\n  .wrap{max-width:var(--max-w); margin:0 auto; padding:0 24px;}\n  .mono{font-family:'IBM Plex Mono', monospace;}\n  .insert{\n    background:var(--insert-bg); color:var(--insert); padding:1px 7px; border-radius:5px;\n    font-size:0.85em; font-weight:700; border:1px solid rgba(182,92,66,0.28);\n  }\n\n  .nav{position:sticky; top:0; z-index:40; background:rgba(11,13,12,0.95); backdrop-filter:blur(8px); border-bottom:1px solid rgba(255,255,255,0.08);}\n  .nav .wrap{max-width:1152px; display:flex; align-items:center; justify-content:space-between; padding:16px 24px;}\n  .brand{display:flex; align-items:center; gap:9px; color:#fff; font-weight:600; font-size:1.1rem; letter-spacing:-0.01em; text-decoration:none;}\n  .brand-logo{height:30px; width:30px; display:block; object-fit:contain; flex-shrink:0; background:transparent !important; border:0 !important; padding:0 !important; border-radius:0 !important; box-shadow:none !important;}\n  .nav-links{display:flex; gap:32px; font-size:14px; color:rgba(255,255,255,0.65);}\n  .nav-links a{text-decoration:none; color:inherit;}\n  .nav-links a:hover{color:#fff;}\n  @media (max-width:760px){ .nav-links{display:none;} }\n\n  .article-hero{padding:56px 0 8px;}\n  .breadcrumb{font-size:13px; color:var(--text-soft); margin-bottom:24px;}\n  .breadcrumb a{color:var(--text-soft); text-decoration:none;}\n  .breadcrumb a:hover{color:var(--emerald-deep);}\n  .r-badge{\n    display:inline-flex; font-size:11px; font-weight:700; letter-spacing:0.05em; text-transform:uppercase;\n    color:var(--emerald-deep); background:var(--emerald-pale); padding:5px 12px; border-radius:100px; margin-bottom:18px;\n  }\n  h1{font-weight:600; letter-spacing:-0.02em; font-size:clamp(1.9rem,4.4vw,2.7rem); line-height:1.12; margin:0 0 18px;}\n  .dek{font-size:18px; color:var(--text-soft); max-width:62ch; margin:0 0 24px;}\n  .article-meta{display:flex; gap:14px; align-items:center; font-size:13px; color:var(--text-soft); font-weight:600; padding-bottom:32px; border-bottom:1px solid var(--line); margin-bottom:40px;}\n  .article-meta .dot{color:var(--line);}\n\n  .hero-img{\n    width:100% !important;\n    max-width:100% !important;\n    aspect-ratio:16\/9 !important;\n    height:auto !important;\n    max-height:428px !important;\n    object-fit:cover !important;\n    border-radius:16px;\n    display:block !important;\n    margin:0 0 40px !important;\n    background:var(--gray-bg);\n  }\n\n  article h2{font-size:1.5rem; font-weight:600; letter-spacing:-0.01em; margin:44px 0 16px;}\n  article p{color:var(--text-soft); font-size:16.5px; line-height:1.75; margin:0 0 18px;}\n  article ul{color:var(--text-soft); font-size:16px; line-height:1.7; padding-left:22px; margin:0 0 20px;}\n  article li{margin-bottom:8px;}\n  article strong{color:var(--black); font-weight:600;}\n\n  .stat-row{display:grid; grid-template-columns:repeat(3,1fr); gap:14px; margin:28px 0 8px;}\n  .stat-box{background:var(--gray-bg); border:1px solid var(--line); border-radius:16px; padding:20px; text-align:center;}\n  .stat-box .num{font-family:'IBM Plex Mono', monospace; font-size:1.5rem; font-weight:600; color:var(--emerald-deep); margin-bottom:6px;}\n  .stat-box .label{font-size:12.5px; color:var(--text-soft); font-weight:600;}\n  @media (max-width:560px){ .stat-row{grid-template-columns:1fr;} }\n\n  .callout{\n    background:var(--black); color:#fff; border-radius:18px; padding:28px 30px; margin:36px 0;\n  }\n  .callout .label{font-size:11.5px; font-weight:700; letter-spacing:0.08em; text-transform:uppercase; color:var(--emerald-bright); margin-bottom:12px;}\n  .callout p{color:rgba(255,255,255,0.7); margin:0 0 12px; font-size:15px;}\n  .callout p:last-child{margin-bottom:0;}\n  .callout strong{color:#fff;}\n\n  .refs{margin-top:60px; padding-top:32px; border-top:1px solid var(--line);}\n  .refs h3{font-size:1.15rem; font-weight:600; margin:0 0 18px;}\n  .refs ol{padding-left:20px; margin:0;}\n  .refs li{font-size:13px; color:var(--text-soft); line-height:1.6; margin-bottom:12px; word-break:break-word;}\n  .refs a{word-break:break-all;}\n\n  footer{background:var(--black); border-top:1px solid rgba(255,255,255,0.08);}\n  footer .wrap{max-width:1152px; display:flex; align-items:center; justify-content:space-between; flex-wrap:wrap; gap:20px; padding:40px 24px;}\n  footer p{color:rgba(255,255,255,0.35); font-size:12px; max-width:420px; text-align:right; margin:0;}\n  @media (max-width:640px){ footer .wrap{flex-direction:column; text-align:center;} footer p{text-align:center;} }\n\n.answer-box{background:var(--emerald-pale);border:1px solid rgba(69,108,87,.24);border-radius:16px;padding:22px 24px;margin:0 0 26px}\n.answer-box .label,.method-box .label,.toc .label{font-size:11px;font-weight:700;letter-spacing:.08em;text-transform:uppercase;color:var(--emerald-deep);margin-bottom:9px}\n.answer-box p{margin:0;color:var(--text-soft);font-size:15.5px}\n.method-box,.toc{background:var(--gray-bg);border:1px solid var(--line);border-radius:14px;padding:18px 20px;margin:0 0 30px}\n.method-box p{margin:0;color:var(--text-soft);font-size:13.5px}\n.toc ul{margin:0;padding-left:18px;font-size:14.5px;color:var(--text-soft)}\n.toc li{margin-bottom:6px}.toc a{color:var(--text-soft);text-decoration:none}\n.compare-grid{display:grid;grid-template-columns:repeat(3,1fr);gap:14px;margin:24px 0 28px}\n.compare-card{background:var(--gray-bg);border:1px solid var(--line);border-radius:16px;padding:18px}\n.compare-card .type{font-size:11px;text-transform:uppercase;letter-spacing:.06em;color:var(--emerald-deep);font-weight:700}\n.compare-card .name{font-weight:700;margin:5px 0}.compare-card p{font-size:14px;margin:0}\n.faq-item{border-bottom:1px solid var(--line);padding:18px 0}.faq-item:first-of-type{border-top:1px solid var(--line)}\n.faq-item h3{margin:0 0 8px;font-size:16px}.faq-item p{margin:0;font-size:15px}\n.related-reading{margin:46px 0 16px;padding:24px 26px;background:var(--gray-bg);border:1px solid var(--line);border-radius:16px}\n.related-reading h2{font-size:1.3rem;margin:0 0 12px}.related-reading li{margin:7px 0}\n@media(max-width:680px){.compare-grid{grid-template-columns:1fr}}\narticle h2[id]{scroll-margin-top:100px}\n\n\n  \/* ---------- MOBILE EXPERIENCE POLISH ---------- *\/\n\n  .menu-button{\n    display:none;\n    align-items:center;\n    justify-content:center;\n    width:44px;\n    height:44px;\n    padding:0;\n    color:#fff;\n    background:transparent;\n    border:1px solid rgba(255,255,255,.22);\n    border-radius:10px;\n    cursor:pointer;\n  }\n\n  .menu-button svg{\n    width:21px;\n    height:21px;\n    fill:none;\n    stroke:currentColor;\n    stroke-width:2;\n    stroke-linecap:round;\n  }\n\n  .mobile-nav{\n    display:none;\n  }\n\n  @media (max-width:760px){\n    .nav .wrap{\n      position:relative;\n      min-height:64px;\n      padding:10px 20px;\n    }\n\n    .brand{\n      min-width:0;\n      gap:8px;\n      font-size:1rem;\n    }\n\n    .brand-logo{\n      width:30px;\n      height:30px;\n    }\n\n    .menu-button{\n      display:inline-flex;\n      flex:0 0 44px;\n    }\n\n    .mobile-nav{\n      position:absolute;\n      top:100%;\n      right:20px;\n      left:20px;\n      z-index:60;\n      max-height:calc(100vh - 64px);\n      max-height:calc(100svh - 64px);\n      padding:8px 12px 12px;\n      overflow-y:auto;\n      overscroll-behavior:contain;\n      background:rgba(11,13,12,.99);\n      border:1px solid rgba(255,255,255,.1);\n      border-top:0;\n      border-radius:0 0 14px 14px;\n      box-shadow:0 14px 30px rgba(0,0,0,.22);\n    }\n\n    .mobile-nav.open{\n      display:grid;\n    }\n\n    .mobile-nav a{\n      display:flex;\n      align-items:center;\n      min-height:48px;\n      padding:11px 10px;\n      color:rgba(255,255,255,.82);\n      text-decoration:none;\n      border-bottom:1px solid rgba(255,255,255,.08);\n    }\n\n    .mobile-nav a:last-child{\n      border-bottom:0;\n    }\n\n    .mobile-nav a:hover,\n    .mobile-nav a:focus-visible{\n      color:#fff;\n      background:rgba(255,255,255,.06);\n    }\n\n    .wrap{\n      padding-left:20px;\n      padding-right:20px;\n    }\n\n    .article-hero{\n      padding:48px 0 6px;\n    }\n\n    .breadcrumb{\n      margin-bottom:18px;\n      font-size:12px;\n      line-height:1.5;\n    }\n\n    .r-badge{\n      margin-bottom:14px;\n      font-size:10.5px;\n      line-height:1.4;\n    }\n\n    h1{\n      margin-bottom:16px;\n      font-size:clamp(2rem,8vw,2.65rem);\n      line-height:1.08;\n    }\n\n    .dek{\n      margin-bottom:20px;\n      font-size:16px;\n      line-height:1.65;\n    }\n\n    .article-meta{\n      flex-wrap:wrap;\n      gap:6px 10px;\n      margin-bottom:28px;\n      padding-bottom:24px;\n      font-size:12px;\n      line-height:1.5;\n    }\n\n    .hero-img{\n      margin-bottom:28px !important;\n      border-radius:14px;\n    }\n\n    .answer-box{\n      padding:20px 22px;\n      margin-bottom:24px;\n      border-radius:15px;\n    }\n\n    .answer-box p{\n      font-size:15px;\n      line-height:1.65;\n    }\n\n    .method-box{\n      padding:16px 18px;\n      margin-bottom:26px;\n      border-radius:14px;\n    }\n\n    .toc{\n      padding:16px;\n      margin-bottom:28px;\n      overflow:hidden;\n      border-radius:14px;\n    }\n\n    .toc .label{\n      margin-bottom:10px;\n    }\n\n    .toc ul{\n      display:flex;\n      gap:8px;\n      width:100%;\n      margin:0;\n      padding:2px 0 4px;\n      overflow-x:auto;\n      list-style:none;\n      overscroll-behavior-inline:contain;\n      scroll-snap-type:x proximity;\n      -webkit-overflow-scrolling:touch;\n      scrollbar-width:none;\n    }\n\n    .toc ul::-webkit-scrollbar{\n      display:none;\n    }\n\n    .toc li{\n      flex:0 0 auto;\n      margin:0;\n      scroll-snap-align:start;\n    }\n\n    .toc a{\n      display:flex;\n      align-items:center;\n      min-height:40px;\n      padding:9px 12px;\n      white-space:nowrap;\n      background:#fff;\n      border:1px solid var(--line);\n      border-radius:999px;\n      font-size:12px;\n      line-height:1.25;\n    }\n\n    article h2{\n      margin:40px 0 13px;\n      font-size:1.42rem;\n      line-height:1.25;\n      scroll-margin-top:88px;\n    }\n\n    article p{\n      margin-bottom:16px;\n      font-size:16px;\n      line-height:1.72;\n    }\n\n    article ul{\n      margin-bottom:18px;\n      padding-left:20px;\n    }\n\n    .stat-row{\n      gap:10px;\n      margin:24px 0 8px;\n    }\n\n    .stat-box{\n      padding:18px;\n      border-radius:14px;\n    }\n\n    .stat-box .num{\n      font-size:1.35rem;\n      line-height:1.2;\n    }\n\n    .stat-box .label{\n      line-height:1.45;\n    }\n\n    .compare-grid{\n      gap:12px;\n      margin:22px 0 26px;\n    }\n\n    .compare-card{\n      padding:18px;\n      border-radius:14px;\n    }\n\n    .compare-card .type{\n      font-size:10.5px;\n    }\n\n    .compare-card .name{\n      margin:5px 0 7px;\n    }\n\n    .compare-card p{\n      font-size:13.5px;\n      line-height:1.62;\n    }\n\n    .callout{\n      padding:22px;\n      margin:28px 0;\n      border-radius:16px;\n    }\n\n    .callout p{\n      font-size:14.5px;\n      line-height:1.65;\n    }\n\n    .faq-item{\n      padding:16px 0;\n    }\n\n    .faq-item h3{\n      line-height:1.4;\n    }\n\n    .faq-item p{\n      font-size:14.5px;\n      line-height:1.65;\n    }\n\n    .related-reading{\n      padding:20px 22px;\n      margin:38px 0 16px;\n      border-radius:15px;\n    }\n\n    .related-reading h2{\n      font-size:1.25rem;\n      line-height:1.3;\n    }\n\n    .related-reading ul{\n      margin-bottom:0;\n    }\n\n    .refs{\n      margin-top:46px;\n      padding-top:24px;\n    }\n\n    footer .wrap{\n      gap:16px;\n      padding:30px 20px;\n    }\n\n    footer p{\n      line-height:1.6;\n    }\n  }\n\n  @media (max-width:560px){\n    .nav .wrap{\n      min-height:62px;\n      padding:9px 16px;\n    }\n\n    .brand{\n      font-size:.96rem;\n    }\n\n    .brand-logo{\n      width:28px;\n      height:28px;\n    }\n\n    .menu-button{\n      width:42px;\n      height:42px;\n      flex-basis:42px;\n    }\n\n    .mobile-nav{\n      right:16px;\n      left:16px;\n    }\n\n    .wrap{\n      padding-left:16px;\n      padding-right:16px;\n    }\n\n    .article-hero{\n      padding-top:40px;\n    }\n\n    .breadcrumb{\n      margin-bottom:15px;\n      font-size:11.5px;\n    }\n\n    .r-badge{\n      margin-bottom:12px;\n      font-size:10px;\n    }\n\n    h1{\n      font-size:clamp(1.82rem,9vw,2.18rem);\n    }\n\n    .dek{\n      margin-bottom:18px;\n      font-size:15px;\n    }\n\n    .article-meta{\n      display:grid;\n      gap:3px;\n      margin-bottom:24px;\n      padding-bottom:20px;\n      font-size:11.5px;\n    }\n\n    .article-meta .dot{\n      display:none;\n    }\n\n    .hero-img{\n      margin-bottom:24px !important;\n      border-radius:12px;\n    }\n\n    .answer-box{\n      padding:18px;\n      margin-bottom:22px;\n      border-radius:14px;\n    }\n\n    .method-box{\n      padding:15px 16px;\n      margin-bottom:24px;\n      border-radius:13px;\n    }\n\n    .toc{\n      padding:14px;\n      margin-bottom:24px;\n    }\n\n    .toc a{\n      min-height:42px;\n    }\n\n    article h2{\n      margin-top:34px;\n      font-size:1.3rem;\n    }\n\n    article p{\n      font-size:15.5px;\n      line-height:1.68;\n    }\n\n    .stat-row{\n      grid-template-columns:1fr;\n    }\n\n    .stat-box{\n      padding:16px;\n    }\n\n    .compare-grid{\n      grid-template-columns:1fr;\n    }\n\n    .compare-card{\n      padding:16px;\n    }\n\n    .callout{\n      padding:18px;\n      margin:24px 0;\n    }\n\n    .faq-item p{\n      font-size:14px;\n    }\n\n    .related-reading{\n      padding:18px;\n      margin-top:32px;\n      border-radius:14px;\n    }\n\n    .related-reading li{\n      font-size:14px;\n      line-height:1.6;\n    }\n\n    .refs{\n      margin-top:40px;\n      padding-top:22px;\n    }\n\n    .refs li{\n      font-size:12px;\n      line-height:1.65;\n    }\n\n    footer .wrap{\n      flex-direction:column;\n      padding:28px 16px;\n      text-align:center;\n    }\n\n    footer p{\n      text-align:center;\n    }\n  }\n\n  @media (max-width:380px){\n    .nav .wrap{\n      padding-left:14px;\n      padding-right:14px;\n    }\n\n    .brand{\n      font-size:.92rem;\n    }\n\n    .mobile-nav{\n      right:14px;\n      left:14px;\n    }\n\n    .wrap{\n      padding-left:14px;\n      padding-right:14px;\n    }\n\n    h1{\n      font-size:1.72rem;\n    }\n\n    .dek{\n      font-size:14.5px;\n    }\n\n    .answer-box,\n    .method-box,\n    .toc,\n    .compare-card,\n    .callout,\n    .related-reading{\n      padding-left:15px;\n      padding-right:15px;\n    }\n\n    footer .wrap{\n      padding-left:14px;\n      padding-right:14px;\n    }\n  }\n\n<\/style><script type=\"application\/ld+json\">\n{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"@id\":\"https:\/\/peptidedeepdive.com\/retatrutide\/#faq\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Is retatrutide FDA-approved?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. The FDA and other regulators have not approved retatrutide. Lilly says it plans a US regulatory submission in Q1 2027.\"}},{\"@type\":\"Question\",\"name\":\"How much weight did people lose on retatrutide in trials?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"In Phase 2, the 12 mg group lost an average of 24.2% at 48 weeks. In addition, Lilly reported 28.3% average weight loss at 80 weeks in the 12 mg TRIUMPH-1 group. A BMI \u226535 extension subgroup averaged 30.3% at 104 weeks.\"}},{\"@type\":\"Question\",\"name\":\"How is retatrutide different from semaglutide and tirzepatide?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Semaglutide mainly targets GLP-1, while tirzepatide targets GIP and GLP-1. By contrast, retatrutide targets GIP, GLP-1 and glucagon receptors, which makes it a triple agonist.\"}},{\"@type\":\"Question\",\"name\":\"Is retatrutide better than tirzepatide?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"We do not know yet. TRIUMPH-5 is directly comparing the two drugs in adults with obesity. However, ClinicalTrials.gov lists primary completion for December 2026, so no completed head-to-head Phase 3 result is available yet.\"}},{\"@type\":\"Question\",\"name\":\"Can you get retatrutide prescribed or compounded?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No FDA-approved prescription product exists today. In addition, FDA has warned online sellers that market retatrutide products as unapproved new drugs. Lilly also says people should not use products that claim to be retatrutide outside Lilly-sponsored trials.\"}},{\"@type\":\"Question\",\"name\":\"Are the 30% weight-loss figures the average for everyone?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. The 30.3% figure comes from a TRIUMPH-1 extension subgroup with a baseline BMI of at least 35. By comparison, the main 12 mg group averaged 28.3% at 80 weeks.\"}}]}\n<\/script><script type=\"application\/ld+json\">\n{\"@context\":\"https:\/\/schema.org\",\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Research\",\"item\":\"https:\/\/peptidedeepdive.com\/research\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Metabolic\",\"item\":\"https:\/\/peptidedeepdive.com\/research\/#metabolic\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Retatrutide\",\"item\":\"https:\/\/peptidedeepdive.com\/retatrutide\/\"}]}\n<\/script><script type=\"application\/ld+json\">\n{\"@context\":\"https:\/\/schema.org\",\"@type\":\"Article\",\"headline\":\"What Is Retatrutide? Triple-Agonist Trial Results & FDA Status\",\"description\":\"What is retatrutide? Review its GLP-1\/GIP\/glucagon triple-agonist mechanism, Phase 2 and Phase 3 weight-loss trial results, side effects, FDA status and how it compares with semaglutide and tirzepatide.\",\"mainEntityOfPage\":{\"@type\":\"WebPage\",\"@id\":\"https:\/\/peptidedeepdive.com\/retatrutide\/\"},\"image\":[\"https:\/\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/ChatGPT-Image-Jul-28-2026-10_50_43-PM.png\"],\"author\":{\"@type\":\"Organization\",\"name\":\"PeptideDeepDive Editorial Team\",\"url\":\"https:\/\/peptidedeepdive.com\/about\/\"},\"publisher\":{\"@type\":\"Organization\",\"name\":\"PeptideDeepDive\",\"url\":\"https:\/\/peptidedeepdive.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\/\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png\"}},\"datePublished\":\"2026-07-28\",\"dateModified\":\"2026-08-12\",\"about\":[\"Retatrutide\",\"What is retatrutide\",\"retatrutide weight loss trial results\",\"retatrutide triple agonist\",\"retatrutide vs semaglutide\",\"retatrutide vs tirzepatide\",\"retatrutide FDA status\"]}\n<\/script>\n<div class=\"nav\">\n<div class=\"wrap\">\n<!-- Use the transparent-background logo file. -->\n<a aria-label=\"PeptideDeepDive home\" class=\"brand\" href=\"https:\/\/peptidedeepdive.com\/\"><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" alt=\"PeptideDeepDive logo\" class=\"brand-logo\" height=\"30\" src=\"https:\/\/i0.wp.com\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png?resize=30%2C30&#038;ssl=1\" width=\"30\">PeptideDeepDive<\/a>\n<div class=\"nav-links\">\n<a href=\"https:\/\/peptidedeepdive.com\/shop\/\">Shop<\/a>\n<a aria-current=\"page\" href=\"https:\/\/peptidedeepdive.com\/research\/\">Research<\/a>\n<a href=\"https:\/\/peptidedeepdive.com\/peptide-coas\/\">Lab Reports<\/a>\n<a href=\"https:\/\/peptidedeepdive.com\/about\/\">About<\/a>\n<a href=\"https:\/\/peptidedeepdive.com\/faq\/\">FAQ<\/a>\n<\/div>\n\n<button class=\"menu-button\" type=\"button\" aria-expanded=\"false\" aria-controls=\"pdd-retatrutide-mobile-nav\" aria-label=\"Open navigation menu\">\n<svg viewBox=\"0 0 24 24\" aria-hidden=\"true\"><path d=\"M4 7h16M4 12h16M4 17h16\"><\/path><\/svg>\n<\/button>\n\n<nav class=\"mobile-nav\" id=\"pdd-retatrutide-mobile-nav\" aria-label=\"Mobile navigation\">\n<a href=\"https:\/\/peptidedeepdive.com\/shop\/\">Shop<\/a>\n<a aria-current=\"page\" href=\"https:\/\/peptidedeepdive.com\/research\/\">Research<\/a>\n<a href=\"https:\/\/peptidedeepdive.com\/peptide-coas\/\">Lab Reports<\/a>\n<a href=\"https:\/\/peptidedeepdive.com\/about\/\">About<\/a>\n<a href=\"https:\/\/peptidedeepdive.com\/faq\/\">FAQ<\/a>\n<\/nav>\n<\/div>\n<\/div>\n<div class=\"wrap\">\n<div class=\"article-hero\">\n<div class=\"breadcrumb\"><a href=\"https:\/\/peptidedeepdive.com\/research\/\">Research<\/a> \/ <a href=\"https:\/\/peptidedeepdive.com\/research\/#metabolic\">Metabolic<\/a> \/ Retatrutide<\/div>\n<span class=\"r-badge\">Guide \u00b7 Investigational Metabolic Drug<\/span>\n<h1>What Is Retatrutide? Triple-Agonist Trial Results &amp; FDA Status<\/h1>\n<p class=\"dek\">Retatrutide is Eli Lilly&#8217;s investigational GLP-1\/GIP\/glucagon triple agonist. Phase 2 and Phase 3 trials have reported unusually large average weight reductions. However, no regulator has approved the drug, and patients cannot get it as a legitimate prescription medicine.<\/p>\n<div class=\"article-meta\">By <a href=\"https:\/\/peptidedeepdive.com\/about\/\">PeptideDeepDive Editorial Team<\/a><span class=\"dot\">\u00b7<\/span><span>Updated 12 August 2026<\/span><span class=\"dot\">\u00b7<\/span><span>10 min read<\/span><\/div>\n<\/div>\n<img data-recalc-dims=\"1\" alt=\"Retatrutide triple agonist trial results, weight loss and FDA status\" class=\"hero-img\" decoding=\"async\" fetchpriority=\"high\" height=\"428\" loading=\"eager\" src=\"https:\/\/i0.wp.com\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/ChatGPT-Image-Jul-28-2026-10_50_43-PM.png?resize=760%2C428&#038;ssl=1\" width=\"760\">\n<section class=\"answer-box\"><div class=\"label\">Retatrutide: quick answer<\/div><p><strong>Retatrutide (LY3437943) is an investigational once-weekly drug that activates GIP, GLP-1 and glucagon receptors.<\/strong> In Phase 2, the 12 mg group lost an average of 24.2% of body weight at 48 weeks. Lilly later reported 28.3% average weight loss at 80 weeks in the 12 mg TRIUMPH-1 group. In addition, a BMI \u226535 extension subgroup reached 30.3% at 104 weeks. Retatrutide is still unapproved, and Lilly plans a US regulatory submission in Q1 2027.<\/p><\/section>\n<div class=\"method-box\"><div class=\"label\">How this guide was reviewed<\/div><p>The <a href=\"https:\/\/peptidedeepdive.com\/about\/\">PeptideDeepDive Editorial Team<\/a> checks claims against peer-reviewed trials, ClinicalTrials.gov and sponsor reports. Importantly, we label topline findings when a full peer-reviewed paper is not yet available. We do not list a clinician reviewer because we have not verified one. Finally, this guide is for education only and does not provide prescribing, sourcing or dosing advice.<\/p><\/div>\n<nav class=\"toc\"><div class=\"label\">In this guide<\/div><ul>\n<li><a href=\"#what-is-retatrutide\">What is retatrutide?<\/a><\/li>\n<li><a href=\"#how-it-works\">How does the triple agonist work?<\/a><\/li>\n<li><a href=\"#trial-results\">What do retatrutide weight-loss trials show?<\/a><\/li>\n<li><a href=\"#comparison\">Retatrutide vs semaglutide vs tirzepatide<\/a><\/li>\n<li><a href=\"#side-effects\">What side effects have trials reported?<\/a><\/li>\n<li><a href=\"#fda-status\">Is retatrutide FDA-approved?<\/a><\/li>\n<li><a href=\"#unknowns\">What is still unknown?<\/a><\/li>\n<li><a href=\"#faq\">Retatrutide FAQ<\/a><\/li>\n<\/ul><\/nav>\n<article>\n<h2 id=\"what-is-retatrutide\">What Is Retatrutide?<\/h2>\n<p>Retatrutide, also known as LY3437943, is an investigational once-weekly peptide-based medicine from Eli Lilly. It activates three metabolic receptors at the same time: GIP, GLP-1 and glucagon. That makes it a GLP-1\/GIP\/glucagon triple agonist. By comparison, semaglutide mainly targets GLP-1, while tirzepatide targets GIP and GLP-1.<\/p>\n<p>The regulatory point is simple: retatrutide remains investigational. Lilly says no regulator has approved it, and legitimate access is limited to Lilly-sponsored trials. Therefore, products sold online as \u201cretatrutide\u201d do not have the same quality or regulatory status as the trial drug.<\/p>\n<h2 id=\"how-it-works\">How Does Retatrutide&#8217;s Triple-Agonist Mechanism Work?<\/h2>\n<p>Retatrutide combines three metabolic signals. GLP-1 and GIP influence appetite, insulin release and blood-sugar control. Meanwhile, glucagon-receptor activity may also affect energy use and fuel metabolism. Researchers designed the triple-agonist approach to test whether that added signal can produce a different effect from single- or dual-receptor medicines.<\/p>\n<p>However, receptor theory does not prove a clinical advantage on its own. Instead, randomized trials must show whether the mechanism leads to meaningful outcomes. Therefore, the Phase 2 and Phase 3 results matter more than the receptor theory alone.<\/p>\n<h2 id=\"trial-results\">What Do Retatrutide Weight-Loss Trial Results Actually Show?<\/h2>\n<p>The foundational Phase 2 obesity trial appeared in the New England Journal of Medicine in 2023. At 48 weeks, the 12 mg group lost an average of 24.2% of body weight, compared with 2.1% in the placebo group. <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2301972\" rel=\"noopener noreferrer\" target=\"_blank\">Read the Phase 2 trial<\/a>.<\/p>\n<p>Phase 3 has since moved the evidence forward. However, the newest obesity findings remain sponsor-reported topline results rather than full peer-reviewed papers. In May 2026, Lilly reported 28.3% average weight loss at 80 weeks in the 12 mg TRIUMPH-1 group. In addition, a study-extension subgroup with a baseline BMI of at least 35 reached 30.3% average weight loss at 104 weeks.<\/p>\n<div class=\"stat-row\">\n<div class=\"stat-box\"><div class=\"num mono\">24.2%<\/div><div class=\"label\">Phase 2 mean weight loss at 48 weeks in the 12 mg group<\/div><\/div>\n<div class=\"stat-box\"><div class=\"num mono\">28.3%<\/div><div class=\"label\">TRIUMPH-1 Phase 3 mean weight loss at 80 weeks in the 12 mg group<\/div><\/div>\n<div class=\"stat-box\"><div class=\"num mono\">30.3%<\/div><div class=\"label\">TRIUMPH-1 extension mean at 104 weeks in the BMI \u226535 subgroup<\/div><\/div>\n<\/div>\n<p>Lilly also reported positive Phase 3 topline results from TRIUMPH-2 and TRIUMPH-3 in July 2026. For example, adults with obesity or overweight plus type 2 diabetes lost up to an average of 20.8% at 80 weeks in TRIUMPH-2. Meanwhile, adults with severe obesity and heart disease lost up to 22.6% at 80 weeks in TRIUMPH-3.<\/p>\n<p>These averages are larger than those typically reported in major obesity trials of semaglutide and tirzepatide. However, cross-trial comparisons do not prove that retatrutide is better. Instead, a direct Phase 3 study must answer that question. TRIUMPH-5 is comparing retatrutide with tirzepatide, and ClinicalTrials.gov lists primary completion for December 2026.<\/p>\n<h2 id=\"comparison\">Retatrutide vs Semaglutide vs Tirzepatide: How Do They Differ?<\/h2>\n<div class=\"compare-grid\">\n<div class=\"compare-card\"><div class=\"type\">Single agonist<\/div><div class=\"name\">Semaglutide<\/div><p>Targets GLP-1. For example, approved products include Wegovy for weight management and Ozempic for type 2 diabetes.<\/p><\/div>\n<div class=\"compare-card\"><div class=\"type\">Dual agonist<\/div><div class=\"name\">Tirzepatide<\/div><p>Targets GIP and GLP-1. In addition, approved products include Zepbound and Mounjaro, depending on indication and country.<\/p><\/div>\n<div class=\"compare-card\"><div class=\"type\">Triple agonist<\/div><div class=\"name\">Retatrutide<\/div><p>Targets GIP, GLP-1 and glucagon. However, the drug remains investigational even as Phase 3 data continue to emerge.<\/p><\/div>\n<\/div>\n<p>The important distinction is evidence and approval status, not just receptor count. Semaglutide and tirzepatide are approved medicines with established labels and regulated supply chains. By contrast, retatrutide remains a development-stage drug. For a broader comparison, see our <a href=\"https:\/\/peptidedeepdive.com\/glp-1\/\">GLP-1 medicines compared<\/a> guide.<\/p>\n<h2 id=\"side-effects\">What Side Effects Have Retatrutide Trials Reported?<\/h2>\n<p>Across Phase 2 and sponsor-reported Phase 3 results, the most common side effects have been gastrointestinal. For example, trials have reported nausea, diarrhea, vomiting and constipation. This pattern resembles the side-effect profile of other incretin-based medicines. However, higher doses and dose increases can affect tolerability, and some participants stopped treatment because of side effects.<\/p>\n<p>The Phase 2 trial also found dose-related increases in heart rate. Those changes peaked earlier in treatment and then declined. Because retatrutide is still under study, longer Phase 3 and outcomes trials remain important for defining its safety profile.<\/p>\n<h2 id=\"fda-status\">Is Retatrutide FDA-Approved? 2026 Regulatory Status<\/h2>\n<div class=\"callout\"><div class=\"label\">Regulatory status, plainly stated<\/div>\n<p><strong>Retatrutide is not FDA-approved, and no other regulator has approved it.<\/strong> Lilly&#8217;s July 2026 update says the company now has enough clinical data to support global submissions and plans a US filing in Q1 2027. Therefore, the accurate August 2026 status is \u201cPhase 3 with positive topline results; regulatory submission planned,\u201d not \u201capproved\u201d or \u201cunder FDA review.\u201d<\/p>\n<p>There is also no legitimate retail prescription version today. In addition, FDA has warned online sellers that market \u201cretatrutide\u201d as an unapproved new drug. Lilly also warns that products sold outside its trials may contain unknown ingredients, contaminants or the wrong amount of active ingredient.<\/p><\/div>\n<p>For current development status, see Lilly&#8217;s <a href=\"https:\/\/www.lilly.com\/news\/stories\/what-to-know-about-retatrutide\" rel=\"noopener noreferrer\" target=\"_blank\">retatrutide explainer<\/a>. In addition, see the <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05929066\" rel=\"noopener noreferrer\" target=\"_blank\">TRIUMPH-1 trial record<\/a>.<\/p>\n<h2 id=\"unknowns\">What Is Still Unknown About Retatrutide?<\/h2>\n<ul><li>Full peer-reviewed reports for the newest Phase 3 obesity results, including detailed safety tables<\/li><li>The result of the direct TRIUMPH-5 retatrutide-versus-tirzepatide trial<\/li><li>Long-term heart and kidney outcomes from TRIUMPH-Outcomes<\/li><li>Final FDA, EMA and MHRA decisions after Lilly files its regulatory package<\/li><li>How well the drug works and how well people tolerate it outside controlled trials if regulators approve it<\/li><\/ul>\n<p>Overall, retatrutide is one of the most important obesity drugs now in development. Its Phase 2 and Phase 3 weight-loss results are notable. However, it is still an unapproved medicine under active study. Therefore, trial results, regulatory approval and real-world treatment should be treated as different stages.<\/p>\n<h2 id=\"faq\">Retatrutide FAQ<\/h2>\n<div class=\"faq-item\"><h3>Is retatrutide FDA-approved?<\/h3><p>No. The FDA and other regulators have not approved retatrutide. Lilly says it plans a US regulatory submission in Q1 2027.<\/p><\/div>\n<div class=\"faq-item\"><h3>How much weight did people lose on retatrutide in trials?<\/h3><p>In Phase 2, the 12 mg group lost an average of 24.2% at 48 weeks. In addition, Lilly reported 28.3% average weight loss at 80 weeks in the 12 mg TRIUMPH-1 group. A BMI \u226535 extension subgroup averaged 30.3% at 104 weeks.<\/p><\/div>\n<div class=\"faq-item\"><h3>How is retatrutide different from semaglutide and tirzepatide?<\/h3><p>Semaglutide mainly targets GLP-1, while tirzepatide targets GIP and GLP-1. By contrast, retatrutide targets GIP, GLP-1 and glucagon receptors, which makes it a triple agonist.<\/p><\/div>\n<div class=\"faq-item\"><h3>Is retatrutide better than tirzepatide?<\/h3><p>We do not know yet. TRIUMPH-5 is directly comparing the two drugs in adults with obesity. However, ClinicalTrials.gov lists primary completion for December 2026, so no completed head-to-head Phase 3 result is available yet.<\/p><\/div>\n<div class=\"faq-item\"><h3>Can you get retatrutide prescribed or compounded?<\/h3><p>No FDA-approved prescription product exists today. In addition, FDA has warned online sellers that market retatrutide products as unapproved new drugs. Lilly also says people should not use products that claim to be retatrutide outside Lilly-sponsored trials.<\/p><\/div>\n<div class=\"faq-item\"><h3>Are the 30% weight-loss figures the average for everyone?<\/h3><p>No. The 30.3% figure comes from a TRIUMPH-1 extension subgroup with a baseline BMI of at least 35. By comparison, the main 12 mg group averaged 28.3% at 80 weeks.<\/p><\/div>\n<\/article>\n<section class=\"related-reading\"><h2>Related GLP-1, Metabolic &amp; Peptide Research<\/h2><ul>\n<li><a href=\"https:\/\/peptidedeepdive.com\/glp-1\/\">GLP-1 medicines compared: semaglutide vs tirzepatide &amp; more<\/a><\/li>\n<li><a href=\"https:\/\/peptidedeepdive.com\/mots-c\/\">MOTS-c mitochondrial peptide evidence &amp; legal status<\/a><\/li>\n<li><a href=\"https:\/\/peptidedeepdive.com\/fda-vs-research-gate\/\">FDA-approved vs research peptides<\/a><\/li>\n<li><a href=\"https:\/\/peptidedeepdive.com\/risks\/\">Peptide stacking &amp; unregulated blend risks<\/a><\/li>\n<li><a href=\"https:\/\/peptidedeepdive.com\/faq\/\">Peptide FAQs: safety, evidence &amp; site policies<\/a><\/li>\n<\/ul><\/section>\n<div class=\"refs\">\n<h3>References<\/h3>\n<ol><li>Jastreboff, A.M. et al. (2023), <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2301972\" rel=\"noopener noreferrer\" target=\"_blank\"><em>Triple-Hormone-Receptor Agonist Retatrutide for Obesity \u2014 A Phase 2 Trial<\/em><\/a>, New England Journal of Medicine, 389:514\u2013526.<\/li><li>Eli Lilly and Company (2026), <a href=\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss\" rel=\"noopener noreferrer\" target=\"_blank\"><em>TRIUMPH-1 Phase 3 topline results<\/em><\/a> \u2014 28.3% mean weight loss at 80 weeks in the 12 mg group and 30.3% in a BMI \u226535 extension subgroup at 104 weeks.<\/li><li>Eli Lilly and Company (2026), <a href=\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-successful-two-additional\" rel=\"noopener noreferrer\" target=\"_blank\"><em>TRIUMPH-2 and TRIUMPH-3 Phase 3 topline results<\/em><\/a> \u2014 July 2026 update and planned US regulatory submission in Q1 2027.<\/li><li>ClinicalTrials.gov, <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05929066\" rel=\"noopener noreferrer\" target=\"_blank\"><em>TRIUMPH-1 (NCT05929066)<\/em><\/a> \u2014 completed Phase 3 obesity trial.<\/li><li>ClinicalTrials.gov, <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06662383\" rel=\"noopener noreferrer\" target=\"_blank\"><em>TRIUMPH-5 (NCT06662383)<\/em><\/a> \u2014 Phase 3 retatrutide-versus-tirzepatide study.<\/li><li>ClinicalTrials.gov, <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06383390\" rel=\"noopener noreferrer\" target=\"_blank\"><em>TRIUMPH-Outcomes (NCT06383390)<\/em><\/a> \u2014 long-term cardiovascular and kidney outcomes trial.<\/li><li>Eli Lilly and Company, <a href=\"https:\/\/www.lilly.com\/news\/stories\/what-to-know-about-retatrutide\" rel=\"noopener noreferrer\" target=\"_blank\"><em>What to know about retatrutide<\/em><\/a> \u2014 current unapproved-status and counterfeit-product warning.<\/li><li>U.S. Food and Drug Administration (2026), <a href=\"https:\/\/www.fda.gov\/inspections-compliance-enforcement-and-criminal-investigations\/warning-letters\/gram-peptides-721806-03312026\" rel=\"noopener noreferrer\" target=\"_blank\"><em>Gram Peptides warning letter<\/em><\/a> \u2014 FDA described online retatrutide products sold by the firm as unapproved new drugs.<\/li><\/ol>\n<\/div>\n<\/div>\n\n<script>\n(function(){\n  var button=document.querySelector('.menu-button');\n  var mobileNav=document.getElementById('pdd-retatrutide-mobile-nav');\n\n  if(button&&mobileNav){\n    button.addEventListener('click',function(){\n      var open=mobileNav.classList.toggle('open');\n      button.setAttribute('aria-expanded',String(open));\n      button.setAttribute('aria-label',open?'Close navigation menu':'Open navigation menu');\n    });\n\n    mobileNav.addEventListener('click',function(event){\n      if(event.target.closest('a')){\n        mobileNav.classList.remove('open');\n        button.setAttribute('aria-expanded','false');\n        button.setAttribute('aria-label','Open navigation menu');\n      }\n    });\n\n    document.addEventListener('keydown',function(event){\n      if(event.key==='Escape'){\n        mobileNav.classList.remove('open');\n        button.setAttribute('aria-expanded','false');\n        button.setAttribute('aria-label','Open navigation menu');\n      }\n    });\n  }\n})();\n<\/script>\n\n<footer>\n<div class=\"wrap\">\n<a aria-label=\"PeptideDeepDive home\" class=\"brand\" href=\"https:\/\/peptidedeepdive.com\/\"><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" alt=\"PeptideDeepDive logo\" class=\"brand-logo\" height=\"30\" src=\"https:\/\/i0.wp.com\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png?resize=30%2C30&#038;ssl=1\" width=\"30\">PeptideDeepDive<\/a>\n<p>Educational content only. Not medical advice. Talk to a qualified healthcare provider before making decisions about your health.<\/p>\n<\/div>\n<\/footer><meta content=\"index,follow,max-image-preview:large\" name=\"robots\"><link as=\"image\" fetchpriority=\"high\" href=\"https:\/\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/ChatGPT-Image-Jul-28-2026-10_50_43-PM.png\" rel=\"preload\"><meta content=\"article\" property=\"og:type\"><meta content=\"PeptideDeepDive\" property=\"og:site_name\"><meta content=\"What Is Retatrutide? Triple-Agonist Trial Results &amp; FDA Status (2026)\" property=\"og:title\"><meta content=\"What is retatrutide? Review its GLP-1\/GIP\/glucagon triple-agonist mechanism, Phase 2 and Phase 3 weight-loss trial results, side effects, FDA status and how it compares with semaglutide and tirzepatide.\" property=\"og:description\"><meta content=\"https:\/\/peptidedeepdive.com\/retatrutide\/\" property=\"og:url\"><meta content=\"https:\/\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/ChatGPT-Image-Jul-28-2026-10_50_43-PM.png\" property=\"og:image\"><meta content=\"Retatrutide triple agonist weight-loss trial results and FDA status\" property=\"og:image:alt\"><meta content=\"2026-07-28T00:00:00+01:00\" property=\"article:published_time\"><meta content=\"2026-08-12T18:18:00+01:00\" property=\"article:modified_time\"><meta content=\"summary_large_image\" name=\"twitter:card\"><meta content=\"What Is Retatrutide? Triple-Agonist Trial Results &amp; FDA Status (2026)\" name=\"twitter:title\"><meta content=\"What is retatrutide? Review its GLP-1\/GIP\/glucagon triple-agonist mechanism, Phase 2 and Phase 3 weight-loss trial results, side effects, FDA status and how it compares with semaglutide and tirzepatide.\" name=\"twitter:description\"><meta content=\"https:\/\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/ChatGPT-Image-Jul-28-2026-10_50_43-PM.png\" name=\"twitter:image\">\n","protected":false},"excerpt":{"rendered":"<p>PeptideDeepDive Shop Research Lab Reports About FAQ Shop Research Lab Reports About FAQ Research \/ Metabolic \/ Retatrutide Guide \u00b7 Investigational Metabolic Drug What Is Retatrutide? Triple-Agonist Trial Results &amp; FDA Status Retatrutide is Eli Lilly&#8217;s investigational GLP-1\/GIP\/glucagon triple agonist. Phase 2 and Phase 3 trials have reported unusually large average weight reductions. However, no <a href=\"https:\/\/peptidedeepdive.com\/nl\/retatrutide\/\" class=\"more-link\">&#8230;<span class=\"screen-reader-text\">  Retatrutide<\/span><\/a><\/p>","protected":false},"author":282947824,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_wpcom_ai_launchpad_about_page":false,"_wpcom_ai_launchpad_gallery_page":false,"_wpcom_ai_launchpad_contact_page":false,"_wpcom_ai_launchpad_events_page":false,"_wpcom_ai_launchpad_video_page":false,"_wpcom_ai_launchpad_portfolio_piece":false,"_zipai_imported":false,"footnotes":""},"class_list":["post-327","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.5 (Yoast SEO v28.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>What is Retatrutide: A New Metabolic Drug Overview - PeptideDeepDive<\/title>\n<meta name=\"description\" content=\"What is Retatrutide? Understand this investigational triple agonist and its promising results in obesity treatment and weight loss.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/peptidedeepdive.com\/nl\/retatrutide\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Retatrutide\" \/>\n<meta property=\"og:description\" content=\"What is Retatrutide? Understand this investigational triple agonist and its promising results in obesity treatment and weight loss.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/peptidedeepdive.com\/nl\/retatrutide\/\" \/>\n<meta property=\"og:site_name\" content=\"PeptideDeepDive\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-23T11:37:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/retatrutide\\\/\",\"url\":\"https:\\\/\\\/peptidedeepdive.com\\\/retatrutide\\\/\",\"name\":\"What is Retatrutide: A New Metabolic Drug Overview - PeptideDeepDive\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/retatrutide\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/retatrutide\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/peptidedeepdive.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/PeptideDeepDiveLogo-transparent.png\",\"datePublished\":\"2026-07-29T20:16:35+00:00\",\"dateModified\":\"2026-09-23T11:37:31+00:00\",\"description\":\"What is Retatrutide? Understand this investigational triple agonist and its promising results in obesity treatment and weight loss.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/retatrutide\\\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/peptidedeepdive.com\\\/retatrutide\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/retatrutide\\\/#primaryimage\",\"url\":\"https:\\\/\\\/peptidedeepdive.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/PeptideDeepDiveLogo-transparent.png\",\"contentUrl\":\"https:\\\/\\\/peptidedeepdive.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/PeptideDeepDiveLogo-transparent.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/retatrutide\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/peptidedeepdive.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Retatrutide\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/#website\",\"url\":\"https:\\\/\\\/peptidedeepdive.com\\\/\",\"name\":\"PeptidesExplained\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/#\\\/schema\\\/person\\\/8aa4df0c53d17a692e53269a6aeb62c2\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/peptidedeepdive.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/peptidedeepdive.com\\\/#\\\/schema\\\/person\\\/8aa4df0c53d17a692e53269a6aeb62c2\",\"name\":\"Laurynas Dabasinskas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586f2b309850fb3714cfa847846917ddcd7734c751912dab6d133d17a26ba12d?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586f2b309850fb3714cfa847846917ddcd7734c751912dab6d133d17a26ba12d?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586f2b309850fb3714cfa847846917ddcd7734c751912dab6d133d17a26ba12d?s=96&d=identicon&r=g\",\"caption\":\"Laurynas Dabasinskas\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586f2b309850fb3714cfa847846917ddcd7734c751912dab6d133d17a26ba12d?s=96&d=identicon&r=g\"},\"sameAs\":[\"http:\\\/\\\/ldabasinskas2003-fozpm.wordpress.com\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"What is Retatrutide: A New Metabolic Drug Overview - PeptideDeepDive","description":"What is Retatrutide? Understand this investigational triple agonist and its promising results in obesity treatment and weight loss.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/peptidedeepdive.com\/nl\/retatrutide\/","og_locale":"nl_NL","og_type":"article","og_title":"Retatrutide","og_description":"What is Retatrutide? Understand this investigational triple agonist and its promising results in obesity treatment and weight loss.","og_url":"https:\/\/peptidedeepdive.com\/nl\/retatrutide\/","og_site_name":"PeptideDeepDive","article_modified_time":"2026-09-23T11:37:31+00:00","og_image":[{"url":"https:\/\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Geschatte leestijd":"8 minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/peptidedeepdive.com\/retatrutide\/","url":"https:\/\/peptidedeepdive.com\/retatrutide\/","name":"What is Retatrutide: A New Metabolic Drug Overview - PeptideDeepDive","isPartOf":{"@id":"https:\/\/peptidedeepdive.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/peptidedeepdive.com\/retatrutide\/#primaryimage"},"image":{"@id":"https:\/\/peptidedeepdive.com\/retatrutide\/#primaryimage"},"thumbnailUrl":"https:\/\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png","datePublished":"2026-07-29T20:16:35+00:00","dateModified":"2026-09-23T11:37:31+00:00","description":"What is Retatrutide? Understand this investigational triple agonist and its promising results in obesity treatment and weight loss.","breadcrumb":{"@id":"https:\/\/peptidedeepdive.com\/retatrutide\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/peptidedeepdive.com\/retatrutide\/"]}]},{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/peptidedeepdive.com\/retatrutide\/#primaryimage","url":"https:\/\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png","contentUrl":"https:\/\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png"},{"@type":"BreadcrumbList","@id":"https:\/\/peptidedeepdive.com\/retatrutide\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/peptidedeepdive.com\/"},{"@type":"ListItem","position":2,"name":"Retatrutide"}]},{"@type":"WebSite","@id":"https:\/\/peptidedeepdive.com\/#website","url":"https:\/\/peptidedeepdive.com\/","name":"PeptidesExplained","description":"","publisher":{"@id":"https:\/\/peptidedeepdive.com\/#\/schema\/person\/8aa4df0c53d17a692e53269a6aeb62c2"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/peptidedeepdive.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":["Person","Organization"],"@id":"https:\/\/peptidedeepdive.com\/#\/schema\/person\/8aa4df0c53d17a692e53269a6aeb62c2","name":"Laurynas Dabasinskas","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/secure.gravatar.com\/avatar\/586f2b309850fb3714cfa847846917ddcd7734c751912dab6d133d17a26ba12d?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/586f2b309850fb3714cfa847846917ddcd7734c751912dab6d133d17a26ba12d?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/586f2b309850fb3714cfa847846917ddcd7734c751912dab6d133d17a26ba12d?s=96&d=identicon&r=g","caption":"Laurynas Dabasinskas"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/586f2b309850fb3714cfa847846917ddcd7734c751912dab6d133d17a26ba12d?s=96&d=identicon&r=g"},"sameAs":["http:\/\/ldabasinskas2003-fozpm.wordpress.com"]}]}},"spectra_blocks_featured_image_url":null,"spectra_blocks_author_info":{"display_name":"Laurynas Dabasinskas","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/586f2b309850fb3714cfa847846917ddcd7734c751912dab6d133d17a26ba12d?s=96&d=identicon&r=g","author_link":"https:\/\/peptidedeepdive.com\/nl\/author\/ldabasinskas2003\/","description":""},"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/PhlgTH-5h","jetpack-related-posts":[{"id":853,"url":"https:\/\/peptidedeepdive.com\/nl\/glp-1\/","url_meta":{"origin":327,"position":0},"title":"GLP-1 Peptide Medicines Compared: Semaglutide, Tirzepatide &amp; More","author":"Laurynas Dabasinskas","date":"augustus 9, 2026","format":false,"excerpt":"GLP-1 Medicines Compared: Semaglutide vs Tirzepatide (2026) PeptideDeepDive Shop Research Lab Reports About FAQ Contact Shop Research Lab Reports About FAQ Contact Home \/ Research \/ GLP-1 Medicines Compared Guide \u00b7 Approved Medicines GLP-1 Medicines Compared in Europe (2026): Semaglutide vs Tirzepatide & More This Europe-focused GLP-1 medicines comparison covers\u2026","rel":"","context":"Soortgelijk bericht","block_context":{"text":"Soortgelijk bericht","link":""},"img":{"alt_text":"PeptideDeepDive logo","src":"https:\/\/i0.wp.com\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]},{"id":680,"url":"https:\/\/peptidedeepdive.com\/nl\/about\/","url_meta":{"origin":327,"position":1},"title":"Over ons","author":"Laurynas Dabasinskas","date":"augustus 4, 2026","format":false,"excerpt":"About PeptideDeepDive: Our Editorial Approach & Standards PeptideDeepDive Shop Research Lab Reports About FAQ Home \/ About The Story Behind It Built Because Clear Answers Were Hard to Find PeptideDeepDive Editorial Team \u00b7 Updated August 2026 I kept seeing the same problem: people were curious about peptides, but the information\u2026","rel":"","context":"Soortgelijk bericht","block_context":{"text":"Soortgelijk bericht","link":""},"img":{"alt_text":"PeptideDeepDive logo","src":"https:\/\/i0.wp.com\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]},{"id":841,"url":"https:\/\/peptidedeepdive.com\/nl\/mots-c\/","url_meta":{"origin":327,"position":2},"title":"MOTS-c Peptide: Evidence, Mitochondrial Function &amp; Legal Status","author":"Laurynas Dabasinskas","date":"augustus 8, 2026","format":false,"excerpt":"MOTS-c Peptide: Evidence, Safety & FDA Status (2026) PeptideDeepDive Shop Research Lab Reports About FAQ Contact Shop Research Lab Reports About FAQ Contact Research \/ Metabolic \/ MOTS-c Peptide Guide \u00b7 Metabolic & Mitochondrial MOTS-c Peptide: Evidence, Safety & Legal Status MOTS-c is a mitochondrial-derived peptide studied in energy metabolism,\u2026","rel":"","context":"Soortgelijk bericht","block_context":{"text":"Soortgelijk bericht","link":""},"img":{"alt_text":"PeptideDeepDive logo","src":"https:\/\/i0.wp.com\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]},{"id":604,"url":"https:\/\/peptidedeepdive.com\/nl\/","url_meta":{"origin":327,"position":3},"title":"Home","author":"Laurynas Dabasinskas","date":"juli 31, 2026","format":false,"excerpt":"PeptideDeepDive Shop Research Lab Reports About FAQ Contact Shop Research Lab Reports About FAQ Contact Evidence-led guides \u00b7 European supplier research Understand European peptide research. Compare suppliers and evidence. Explore European peptide research through evidence-led guides, supplier comparisons and batch-level lab reports. We separate published findings from supplier claims and\u2026","rel":"","context":"Soortgelijk bericht","block_context":{"text":"Soortgelijk bericht","link":""},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":1088,"url":"https:\/\/peptidedeepdive.com\/nl\/what-is-ghk-cu\/","url_meta":{"origin":327,"position":4},"title":"What Is GHK-Cu?","author":"Laurynas Dabasinskas","date":"augustus 19, 2026","format":false,"excerpt":"GHK-Cu Copper Peptide: Evidence, Safety & Status (2026) | PeptideDeepDive PeptideDeepDive Shop Research Lab Reports About FAQ Contact Shop Research Lab Reports About FAQ Contact Research \/ Individual Guides \/ GHK-Cu Guide \u00b7 Skin & Repair GHK-Cu Copper Peptide: Evidence, Safety & Regulation GHK-Cu is a natural copper peptide studied\u2026","rel":"","context":"Soortgelijk bericht","block_context":{"text":"Soortgelijk bericht","link":""},"img":{"alt_text":"PeptideDeepDive logo","src":"https:\/\/i0.wp.com\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]},{"id":826,"url":"https:\/\/peptidedeepdive.com\/nl\/bpc-157-legal\/","url_meta":{"origin":327,"position":5},"title":"BPC-157: Legal Status, Human Evidence &amp; How It Compares","author":"Laurynas Dabasinskas","date":"augustus 8, 2026","format":false,"excerpt":"BPC-157 Legal Status UK\/EU (2026) | PeptideDeepDive PeptideDeepDive Shop Research Lab Reports About FAQ Contact Shop Research Lab Reports About FAQ Contact Research \/ Individual Guides \/ BPC-157 Legal Status & Evidence Guide \u00b7 Recovery & Repair BPC-157 Legal Status, Human Evidence & UK\/EU Regulation (2026) Is BPC-157 legal in\u2026","rel":"","context":"Soortgelijk bericht","block_context":{"text":"Soortgelijk bericht","link":""},"img":{"alt_text":"PeptideDeepDive logo","src":"https:\/\/i0.wp.com\/peptidedeepdive.com\/wp-content\/uploads\/2026\/07\/PeptideDeepDiveLogo-transparent.png?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]}],"_links":{"self":[{"href":"https:\/\/peptidedeepdive.com\/nl\/wp-json\/wp\/v2\/pages\/327","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/peptidedeepdive.com\/nl\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/peptidedeepdive.com\/nl\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/peptidedeepdive.com\/nl\/wp-json\/wp\/v2\/users\/282947824"}],"replies":[{"embeddable":true,"href":"https:\/\/peptidedeepdive.com\/nl\/wp-json\/wp\/v2\/comments?post=327"}],"version-history":[{"count":10,"href":"https:\/\/peptidedeepdive.com\/nl\/wp-json\/wp\/v2\/pages\/327\/revisions"}],"predecessor-version":[{"id":1615,"href":"https:\/\/peptidedeepdive.com\/nl\/wp-json\/wp\/v2\/pages\/327\/revisions\/1615"}],"wp:attachment":[{"href":"https:\/\/peptidedeepdive.com\/nl\/wp-json\/wp\/v2\/media?parent=327"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}